Quadrant Capital Group’s Autolus Therapeutics AUTL Stock Holding History

Quadrant Capital Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,024	Closed	-$4.69K	–	1444
2025 Q1	$4.69K	Hold	3,024	–	–	﹤0.01%	2366
2024 Q4	$7.11K	Hold	3,024	–	–	﹤0.01%	2218
2024 Q3	$11K	Hold	3,024	–	–	﹤0.01%	2118
2024 Q2	$10.5K	Hold	3,024	–	–	﹤0.01%	2100
2024 Q1	$19.3K	Hold	3,024	–	–	﹤0.01%	1866
2023 Q4	$19.5K	Hold	3,024	–	–	﹤0.01%	1841
2023 Q3	$7.05K	Hold	3,024	–	–	﹤0.01%	2080
2023 Q2	$7.2K	Sell	3,024 -850	-22%	-$2.02K	﹤0.01%	2113
2023 Q1	$7.13K	Buy	3,874 +3,024	+356%	+$5.91K	﹤0.01%	2153
2022 Q4	$1.61K	Sell	850 -71	-8%	-$180	﹤0.01%	2467
2022 Q3	$2K	Buy	+921	New	+$2.73K	﹤0.01%	2335
2022 Q2	–	Sell	-3,087	Closed	-$13K	–	2528
2022 Q1	$13K	Sell	3,087 -726	-19%	-$3.05K	﹤0.01%	1522
2021 Q4	$20K	Buy	3,813 +369	+11%	+$2.21K	﹤0.01%	1301
2021 Q3	$23K	Buy	3,444 +1,194	+53%	+$7.54K	﹤0.01%	1178
2021 Q2	$15K	Buy	+2,250	New	+$14K	﹤0.01%	1341

Other funds holding AUTL

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Quadrant Capital Group's AUTL Position: Q2 2025 in Review

Quadrant Capital Group sold out of Autolus Therapeutics (AUTL) in Q2 2025, closing a stake of 3,024 shares — an estimated $4.69K sold.

Quadrant Capital Group first reported a position in AUTL in Q2 2021 and held it in 15 quarters. The position peaked at $23K in Q3 2021. 94 funds tracked by Wall St. Rank hold AUTL as of Q2 2025.

Quadrant Capital Group reported no remaining Autolus Therapeutics position as of Q2 2025 after selling out during the quarter.
Quadrant Capital Group sold 3,024 Autolus Therapeutics shares in Q2 2025, an estimated $4.69K.
Quadrant Capital Group first reported a position in Autolus Therapeutics in Q2 2021 and held it in 15 quarters.
Quadrant Capital Group's Autolus Therapeutics position peaked at $23K in Q3 2021.
94 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.